Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Co-Exclusive License: Convection Enhanced Drug Delivery for Transforming Growth Factor Alpha (TGFα) Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before July 7, 2003 will be considered.
View Prospective Grant of Exclusive License: The Use of the Domain-Swapped Dimer of Cyanovirin (deltaQ50-CVN) in a Topical Microbicide To Prevent the Transmission of HIV and Other Sexually Transmitted Diseases Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 23, 2003, will be considered.
View Prospective Grant of Exclusive License: The Systemic In Vivo Use of the Domain-Swapped Dimer of Cyanovirin (DeltaQ50-CVN) as a Prophylactic or Therapeutic Against HIV and Enveloped Viruses That Cause Hemorrhagic Fever; the Ex Vivo Use of the Domain-Swapped Dimer of Cyanovirin (DeltaQ50-CVN) To Remove or Inactivate HIV in Fluid Samples Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 23, 2003 will be considered.
View Prospective Grant of Exclusive License: Use of Hydroxyurea Alone and in Combination with dNTP Competitors for Blocking Reverse Transcriptase Dependent Viruses Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before June 17, 2003 will be considered.
View Prospective Grant of Exclusive License: β2 Microglobulin Fusion Proteins and High Affinity Variants Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 16, 2003 will be considered.
View Prospective Grant of Exclusive License: Diagnostics of Fungal Infections 1/12/2001.
View Prospective Grant of Exclusive License: Human Monoclonal Antibody Biotherapeutics for the Treatment of HIV Infections Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 12, 2003 will be considered.
View Prospective Grant of Exclusive License: Protein/Peptide Biotherapeutics for the Treatment of HIV Infections Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 9, 2003, will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Protein Biopharmaceuticals for Treatment of HIV Infections Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 5, 2003 will be considered.
View Prospective Grant of Exclusive License: Human Monoclonal Antibody Biotherapeutics for the Treatment of Hepatitis C (HCV) Infections Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 5, 2003 will be considered.
View Cooperative Research and Development Agreement
View Prospective Grant of Exclusive License: Vaccines Against Rotavirus Disease Only written comments and/or applications for a license which are received by NIH on or before April 15, 2003 will be considered.
View Prospective Grant of Exclusive License: Novel Vaccinia Virus Vector for the Treatment of Human Cancers Only written comments and/or license applications which are received by the National Institutes of Health on or before April 14, 2003, will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: “Interleukin-2 Receptor and Applications Thereof” Only written comments and/or license applications which are received by the National Institutes of Health on or before April 7, 2003 will be considered.
View Prospective Grant of Exclusive License: “Spatially and Temporal Control of Gene Expression Protein Promoter in Combination with Local Heat” Only written comments and/or license applications which are received by the National Institutes of Health on or before April 7, 2003 will be considered.
View Prospective Grant of Exclusive License: Nucleic Acid Vaccines for Prevention of Flavivirus Infection
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Methods and Compositions for the Promotion of Hair Growth Utilizing Actin Binding Peptides Only written comments and/or license applications which are received by the National Institutes of Health on or before February 24, 2003, will be considered.
View Prospective Grant of Exclusive License: “Coil for Transcranial Magnetic Stimulation” Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before February 7, 2003, will be considered.
View Prospective Grant of Exclusive License: Conjugate Vaccines To Prevent Diseases Caused by Nontypeable Haemophilus Influenzae and Moraxella Catarrhalis, Particularly Otitis Media Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before January 28, 2003 will be considered.
View National Cancer Institute: Chemical Optimization of Molecular-Targeted Anticancer, Antiviral and Antimicrobial Drug Leads Inquiries regarding CRADA proposals and scientific matters may be forwarded at any time. Confidential CRADA proposals, preferably two pages or less, must be submitted to the NCI. Review of proposals will begin within 90 days from date of this publication and will continue until a suitable collaborator(s) is identified. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest.
View Prospective Grant of Exclusive License: Pharmaceutical Methods of Delivering Folic Acid in a Hormonal Replacement or Contraceptive Composition 04/16/1999. Domestic Status: Patent No.: 6,190,693. Issue Date: 02/20/2001.
View Prospective Grant of Co-Exclusive License: “Endotracheal Tube Using Leak Hole To Lower Resistance and Dead Space” Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before December 30, 2002 will be considered.